What it is and how it works
From the published literature on Dulaglutide; the papers are listed at the end. Research summary, not a recommendation.
What it is
Dulaglutide is a long-acting GLP-1 receptor agonist made by Eli Lilly and sold as Trulicity. It is a large fusion protein: two copies of a modified human GLP-1 peptide (a gut hormone) are joined by a short linker to a fragment of a human antibody (the IgG4 Fc region), which slows its removal from the body enough for once-weekly injection. The FDA approved it in 2014 for type 2 diabetes, and in 2020 added a label claim for lowering cardiovascular risk based on the REWIND trial.
How it works
Dulaglutide binds the GLP-1 receptor, a sensor on pancreatic beta cells, the brain and the gut that normally responds to the hormone released after a meal. On beta cells it increased insulin release only when blood glucose was raised, which limited the risk of low blood sugar when used alone. It also lowered glucagon (the hormone that tells the liver to release glucose), slowed stomach emptying and acted on appetite centres in the brain, which reduced food intake and body weight. The antibody fragment protects the peptide from breakdown by the enzyme DPP-4 and from rapid clearance by the kidney, which is why it lasts about a week. In large outcome trials the drug class also lowered rates of heart attack, stroke and kidney decline in people with type 2 diabetes.
What it has been studied for
- Blood-glucose control in type 2 diabetes (AWARD trial program)
- Reducing heart attack, stroke and cardiovascular death in type 2 diabetes (REWIND)
- Slowing kidney decline in type 2 diabetes with chronic kidney disease (AWARD-7, REWIND renal analysis)
- Head-to-head comparison with semaglutide (SUSTAIN 7)
Strength of the evidence
Approved drugDulaglutide is FDA- and EMA-approved for type 2 diabetes, backed by phase 3 trials and a large placebo-controlled cardiovascular outcome trial.
What the literature reports on safety
Trials most often reported nausea, vomiting, diarrhoea and reduced appetite, mainly early in treatment; pancreatitis, gallbladder disease and low blood sugar when combined with insulin or sulfonylureas are listed risks. The US label carries a boxed warning because GLP-1 agonists caused thyroid C-cell tumours in rodents, and it is contraindicated in people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Trulicity is a prescription drug; it is a large protein that is not on the FDA compounding lists, so product sold outside licensed pharmacies is unregulated.
Key papers
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. (opens in a new tab)
Review · Nauck MA, Quast DR, et al. · Molecular Metabolism (2021) · PMID 33068776
Reviewed the GLP-1 agonist class, including dulaglutide, covering shared mechanisms, glucose and weight effects, the absence of an intrinsic hypoglycaemia risk, and cardiovascular outcome trials.
Review · Kristensen SL, Rørth R, et al. · Lancet Diabetes and Endocrinology (2019) · PMID 31422062
Pooled the large outcome trials, including REWIND, and found the class reduced major cardiovascular events, death from any cause and a composite kidney outcome compared with placebo.
Randomized trial · Gerstein HC, Colhoun HM, et al. · Lancet (2019) · PMID 31189511
In 9901 people with type 2 diabetes, aged 50 or older with either a previous cardiovascular event or cardiovascular risk factors, followed for a median of 5.4 years, dulaglutide reduced the combined rate of heart attack, stroke and cardiovascular death compared with placebo; death from any cause did not differ significantly, and gastrointestinal adverse events were more common (47.4% versus 34.1%).
Randomized trial · Gerstein HC, Colhoun HM, et al. · Lancet (2019) · PMID 31189509
An exploratory analysis of REWIND found fewer kidney outcomes with dulaglutide, driven mainly by less new-onset heavy protein loss in the urine.
Randomized trial · Tuttle KR, Lakshmanan MC, et al. · Lancet Diabetes and Endocrinology (2018) · PMID 29910024
In people with type 2 diabetes and moderate-to-severe kidney disease, dulaglutide lowered blood glucose as well as insulin glargine and was associated with a slower decline in kidney filtration.
Randomized trial · Pratley RE, Aroda VR, et al. · Lancet Diabetes and Endocrinology (2018) · PMID 29397376
In a head-to-head trial in 1201 patients, semaglutide produced larger reductions in HbA1c and body weight than dulaglutide with a similar safety profile; gastrointestinal disorders were the most common adverse events in every group.
Sources checked: PubMed/PMC (E-utilities esummary on every PMID), written 2026-11-06.
No sources yet
None of the three teachers' sources we have indexed discuss Dulaglutide yet. This page will fill in as sources are added.
Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.
Disclaimer: for research purposes only
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.